Amplia Therapeutics Ltd has released a press release.
Interim Data From Accent Pancreatic Cancer Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Amplia Therapeutics
- Sixth Confirmed Response in Pancreatic Cancer Trial
- FDA Fast Track Designation for Narmafotinib
- Fifth Confirmed Response in ACCENT Trial
- Amplia Receives R&D Tax Rebate Totalling $3.2 Million
- Granting of Key Patent in Europe and Japan
Later from Amplia Therapeutics
- Amplia to Raise up to $13m for ACCENT and US Trials
- Capital Raise Presentation
- Amplia Successfully Completes Institutional Offer
- Security Class Suspension from Quotation
- App 4D and Financial Report Half Year ended 30 Sep 2024
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics